AUS
NZ
UK
CA
USA
IND
Highlights:
- WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar.
- In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed.
- Monkeypox is a disease that causes rash turning to lesions filled with fluid.
- The Australian government has declared it as of ‘national significance’.
Originated in Africa, Monkeypox, is gradually spreading across the world. The World Health Organisation (WHO) has declared it as an emergency due to the rising cases of Monkeypox in 74 countries so far.
Followed by WHO’s announcement, the Australian government declared the situation of ‘national significance’ in the country. The country has reported total 44 confirmed cases of Monkeypox across several parts.
The concerned Aussie government is currently making efforts to spread the needed awareness about the contagious disease.
Now, as the issue has become of ‘national significance’, it is bound to cast an effect on the sectors impacting economy, healthcare being one of them.
Here, in this story, we are focusing on the performance of four leading healthcare stocks listed on ASX - CSL, Telix, Clinuvel, and Neuren.
Meanwhile, the benchmark S&P/ASX 200 Health Care sector (ASX:XHJ) closed today’s session in red, down 0.04% at 42,677.756 points.
Image Source © 2022 Kalkine Media ®
CSL Limited (ASX:CSL)
Leading Australian biotechnology firm CSL Limited (ASX:CSL) shares closed a tad lower on the ASX today (28 July). CSL’s share price stood at AU$291.400 per share, down 0.147%.
In a year’s time, CSL’s share price has gained 0.13% on the ASX. On year-to-date basis, CSL has lost 1.55% (as of 4:10 PM AEST on the ASX today).
Telix Pharmaceuticals Limited (ASX:TLX)
Cancer treatment developer Telix Pharmaceuticals Limited (ASX:TLX) shares closed 2.100% strong at AU$7.290 per share on the ASX today.
In a year’s time, Telix’s share price gained significantly by 36.52% on the ASX. However, on a year-to-date basis, Telix’s share price has fallen by 11.31%. In last one month, the pharma company has gone up 59.17% on the ASX.
Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australian drug developer Clinuvel Pharmaceuticals Limited (ASX:CUV) shares closed 4.245% strong at AU$17.680 per share on the ASX today.
Clinuvel’s share price has fallen 40.51% on the ASX in last one year. On year-to-date basis, the share price fell 38.89% (as of 4:10 PM AEST on the ASX today).
Neuren Pharmaceuticals Limited (ASX:NEU)
Australian biotechnology firm Neuren Pharmaceuticals Limited (ASX:NEU) shares closed 5.088% at AU$5.370 per share.
Neuren’s share price has gained significantly by 233.54% on the ASX in last 12 months. On year-to-date basis, the share price has gone up 37.69%.
